Abbvie Inc. vs Neurocrine Biosciences Inc
ABBV vs NBIX — side-by-side comparison from reported financials. ABBV leads 4, NBIX leads 7 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Neurocrine Biosciences Inc
NBIX · Healthcare
$142.44+0.84%Strong
| Metric | ABBV | NBIX |
|---|---|---|
| Price | $276.43 | $142.44 |
| Market cap | $488B | $14.5B |
| Revenue (TTM) | $64.4B | $3.37B |
| Revenue growth | +1.8% | +24.3% |
| Net margin | 9.8% | 20.9% |
| Free cash flow | $18.2B | $866M |
| Net cash (debt) | ($56.2B) | $1.01B |
| 1-year price return | +19.8% | +2.9% |
| P/E | 77.4 | 20.5 |
| P/E vs own history (cheap-side %) | 23% | 90% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 21% |
| Altman Z-score | 2.33 | 6.23 |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 2,500 |
Full résumé-style profiles: ABBV CV · NBIX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.